| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 0.0 | 0.0 | 0.0 |
| Other income | 0.1 | 0.1 | 1.0 |
| Total income | 0.1 | 0.1 | 1.0 |
| Profit before exceptional items & tax | 0.1 | 0.0 | 0.9 |
| Profit before tax | 0.1 | 0.0 | 0.9 |
| Net profit | 0.3 | -1.6 | 0.7 |
| Operating margin | 100.0% | 0.0% | 90.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -57.10% |
|---|---|
| Operating profit, year on year | +100.00% |
| Operating profit, quarter on quarter | +100.00% |
BSE results filing, NSE: BACPHAR. Figures extracted from the filing.
Bacil Pharma Ltd: key numbers
- Share price
- ₹25.50
- Market cap
- ₹36.60 Cr
- Revenue (annual)
- ₹0.00 Cr
- Net profit (annual)
- ₹1.56 Cr
- P/E (TTM)
- 55.8×Sector 47.4×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bacil Pharma Ltd
All →Bacil Pharma Annual Report
Bacil Pharma Limited submitted its 39th Annual Report for FY 2025-26. The Annual General Meeting is scheduled for September 23, 2026, via video conferencing.
Bacil Pharma Annual General Meeting
Bacil Pharma Limited has announced book closure dates from September 17 to September 23, 2026, for its 39th Annual General Meeting.
Bacil Pharma Board Meeting Date
Bacil Pharma Limited has scheduled a board meeting for August 29, 2026, to discuss and approve the notice and scheduling of its 39th Annual General Meeting.
Bacil Pharma Board Meeting Outcome
Bacil Pharma Limited announced the appointment of Mr. Mahesh Singh and Mr. Anil Shiv Charan Singh as Additional Directors following its board meeting.
Bacil Pharma Board Meeting Date
Bacil Pharma Ltd has scheduled a Board Meeting for August 25, 2026. The agenda includes the discussion on the appointment of directors.
Bacil Pharma Board Meeting Date
Bacil Pharma Limited has scheduled a board meeting for August 12, 2026, to consider and approve the unaudited financial results for the quarter ending June 30, 2026.